We aimed to compare hypofibrinogenaemia prevalence in major bleeding patients across all clinical contexts, fibrinogen supplementation practice, and explore the relationship between fibrinogen concentrations and mortality. This cohort study included all adult patients from 20 hospitals across Australia and New Zealand who received massive transfusion between April 2011 and October 2015. Of 3566 patients, 2829 (79%) had fibrinogen concentration recorded, with a median first and lowest concentration of 2路0聽g/l (interquartile range [IQR] 1路5-2路7) and 1路8聽g/l (IQR 1路3-2路4), respectively. Liver transplant (1路7聽g/l, IQR 1路2-2路1), trauma (1路8, IQR 1路3-2路5) and vascular surgery (1路9聽g/l, IQR 1路4-2路5) had lower concentrations. Total median fibrinogen dose administered from all products was 7路3聽g (IQR 3路3-13路0). Overall, 1732 (61%) received cryoprecipitate and 9 (<1%) fibrinogen concentrate. Time to cryoprecipitate issue in those with initial fibrinogen concentration <1聽g/l was 2路5聽h (IQR 1路2-4路3聽h). After adjustment, initial fibrinogen concentration had a U-shaped association with in-hospital mortality [adjusted odds ratios: fibrinogen <1聽g/l, 2路31 (95% confidence interval (CI) 1路48-3路60); 1-1路9聽g/l, 1路29 (95% CI 0路99-1路67) and >4聽g/l, 2路03 (95% CI 1路35-3路04), 2-4聽g/l reference category]. The findings indicate areas for practice improvement including timely administration of cryoprecipitate, which is the most common source of concentrated fibrinogen in Australia and New Zealand.